A CME Symposium Held Adjunct with the 2026 ASCO® Annual Meeting
Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 8:30 PM — Educational Meeting
Meeting Room
Continental Room B (Lobby Level)
No registration fee is charged for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.
Faculty
Faculty
Floor J Backes
MD
The Ohio State University College of Medicine, The James Cancer Hospital and Solove Research Institute, Columbus, Ohio
Professor, Larry J Copeland Professorship in Gynecologic Oncology, Director of Clinical Research, Associate Fellowship Director, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
Faculty
Brian M Slomovitz
MD
Mount Sinai Medical Center, Miami, Florida
Professor, OB-GYN, Florida International University, Director, Gynecologic Oncology, Co-Chair, Cancer Research Committee
Moderator
Shannon N Westin
MD, MPH, FASCO, FACOG
The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor, Medical Director, Gynecologic Oncology Center, Director, Early Drug Development, Department of Gynecologic Oncology and Reproductive Medicine
This activity is supported by educational grants from Eisai Inc, Gilead Sciences Inc, GSK, Karyopharm Therapeutics, and Merck.
Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 8:30 PM — Educational Meeting
MODULE 1: Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC)
- Histologic subtypes and major molecular subgroups of EC; implications for prognosis and therapeutic decision-making
- Optimal approaches to biomarker testing for patients with newly diagnosed advanced EC; implications of biomarker status for treatment decision-making
- Similarities and differences in the designs and enrolled populations of the Phase III RUBY, NRG-GY018 and DUO-E trials evaluating the addition of dostarlimab, pembrolizumab and durvalumab, respectively, to platinum-based chemotherapy as first-line treatment for advanced or recurrent EC
- Published efficacy and safety outcomes from the RUBY, NRG-GY018 and DUO-E trials
- Antitumor activity observed with chemotherapy in combination with dostarlimab, pembrolizumab and durvalumab, respectively, in various patient subgroups —based on microsatellite instability (MSI)/mismatch repair (MMR) status, HER2 status, molecular subtype, et cetera — in the RUBY, NRG-GY018 and DUO-E trials
- FDA approvals of dostarlimab and pembrolizumab in combination with chemotherapy for patients with advanced or recurrent EC regardless of MMR status; optimal incorporation into up-front therapy
- Ongoing Phase III studies, such as DOMENICA and KEYNOTE-C93, evaluating first-line anti-PD-1/PD-L1 inhibitor monotherapy for MSI-high /MMR-deficient advanced or recurrent EC
MODULE 2: Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC
- Rationale for the evaluation of PARP inhibition for advanced EC; possible therapeutic synergy between anti-PD-1/PD-L1 antibodies and PARP inhibitors
- Key efficacy and safety findings from the Phase III RUBY Part 2 and DUO-E trials evaluating first-line chemoimmunotherapy followed by anti-PD-1/PD-L1 antibody/PARP inhibitor maintenance therapy for newly diagnosed advanced or recurrent EC
- Outcomes with PARP inhibitors in various patient subsets of the RUBY Part 2 and DUO-E studies
- Potential patient selection for and role of anti-PD-1/PD-L1 antibody/PARP inhibitor maintenance therapy for advanced EC
- Long-term efficacy and safety findings from the Phase III KEYNOTE-775 trial comparing lenvatinib/pembrolizumab to chemotherapy for patients with advanced EC previously treated with a platinum-based regimen
- Strategies to safely and effectively utilize pembrolizumab/lenvatinib; approaches to dosing and side-effect prevention and management
- Current role of pembrolizumab/lenvatinib in EC management algorithms
MODULE 3: Promising Agents Under Investigation for EC
- Biological rationale for the evaluation of TROP2-directed antibody-drug conjugates (ADCs) for advanced EC
- Preliminary efficacy and safety findings reported with TROP2-directed ADCs for patients with pretreated advanced EC
- Emerging positive findings from the Phase III TroFuse-005 trial of sacituzumab tirumotecan versus chemotherapy for patients with advanced or recurrent EC who have experienced disease progression after platinum-based chemotherapy and an anti-PD-1/PD-L1 antibody
- Other ongoing Phase III trials evaluating TROP2-directed ADCs
- Mechanism of action of selinexor and biological rationale for its evaluation in EC, particularly for TP53 wild-type disease
- Updated efficacy and safety findings with and ongoing Phase III evaluation of selinexor as maintenance therapy after first-line chemotherapy for patients with TP53 wild-type advanced or recurrent EC
- Other promising agents and strategies, including B7-H4-targeted ADCs, under investigation for advanced EC
Target Audience
This activity is intended for medical and gynecologic oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of endometrial cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
- Assess the clinical and biological characteristics of the various histologic subtypes and molecular subgroups of endometrial cancer (EC), and consider the implications for prognosis, biomarker evaluation and therapeutic decision-making.
- Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent EC, and educate patients with microsatellite instability-high/mismatch repair (MMR)-deficient or microsatellite-stable/MMR-proficient disease about this novel strategy.
- Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC.
- Review available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and select patients with metastatic EC to receive this novel approach.
- Recognize the biological rationale for the evaluation of trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugates for patients with EC, and consider available research findings with and potential of these agents.
- Recognize adverse events associated with available and investigational therapies used in the treatment of EC to educate patients and manage complications.
- Describe the scientific justification for, published research data with and current studies of novel agents and strategies for EC, and effectively prioritize clinical trial opportunities for eligible patients.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Dr Backes — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, ImmunoGen Inc, Merck, Tubulis; Contracted Research: ImmunoGen Inc, Merck, Natera Inc; Data and Safety Monitoring Boards/Committees: MacroGenics Inc. Dr Slomovitz — Advisory Committees: Aadi Bioscience, AstraZeneca Pharmaceuticals LP, BeOne, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, Gilead Sciences Inc, GSK, Immunocore, Incyte Corporation, Karyopharm Therapeutics, Merck, Novocure Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Consulting Agreements: Aadi Bioscience, AstraZeneca Pharmaceuticals LP, Genmab US Inc, GSK, Karyopharm Therapeutics, Seagen Inc; Data and Safety Monitoring Boards/Committees: Genelux.
MODERATOR
Dr Westin — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Faeth Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Ottimo Pharma, Pfizer Inc, pharmaand GmbH, PMV Pharma, Seagen Inc, Verastem Inc, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Verastem Inc, Zentalis Pharmaceuticals.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
Supporters
This activity is supported by educational grants from Eisai Inc, Gilead Sciences Inc, GSK, Karyopharm Therapeutics, and Merck.
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400
Meeting Room
Continental Room B (Lobby Level)
Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.
Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.
Our onsite registration desk will open at 6:30 PM on Sunday, May 31st. If you are interested in attending, please visit the registration desk outside Continental Room B (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).
Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.
If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
